Trial Profile

Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Tocilizumab (CTOT-45)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Corticosteroids; Mycophenolate mofetil; Tacrolimus
Indications Inflammation; Lung transplant rejection; Postoperative complications
Focus Therapeutic Use
Acronyms ALL IN LUNG; CTOT-45

Most Recent Events

29 Jan 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 8 Jan 2024 to 1 Feb 2024.
03 Jan 2024 Planned End Date changed from 31 Oct 2028 to 8 Jan 2029.
03 Jan 2024 Planned primary completion date changed from 31 Oct 2028 to 8 Jan 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com